INmune Bio, Inc. (INMB)

INmune Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.01	0.16	0.37	0.18	0.01
Revenue Growth (YoY)	-90.97%	-58.56%	106.63%	1545.45%	-
Gross Profit	0.01	0.16	0.37	0.18	0.01
Selling, General & Admin	9.48	9.62	9.26	8.79	6.32
Research & Development	33.17	20.27	17.07	20.54	5.92
Operating Expenses	42.65	29.9	26.33	29.33	12.24
Operating Income	-42.64	-29.74	-25.95	-29.15	-12.23
Interest Expense	-0.79	-2.28	-2.01	-	-
Interest & Investment Income	0.7	-	-	-	-
Other Non Operating Income (Expenses)	0.64	2.01	0.67	-1.19	0.03
EBT Excluding Unusual Items	-42.08	-30.01	-27.3	-30.34	-12.2
Other Unusual Items	-	-	-	-	0.1
Pretax Income	-42.08	-30.01	-27.3	-30.34	-12.1
Net Income	-42.08	-30.01	-27.3	-30.34	-12.1
Net Income to Common	-42.08	-30.01	-27.3	-30.34	-12.1
Shares Outstanding (Basic)	20	18	18	16	12
Shares Outstanding (Diluted)	20	18	18	16	12
Shares Change (YoY)	10.92%	0.30%	11.14%	34.55%	16.70%
EPS (Basic)	-2.11	-1.67	-1.52	-1.88	-1.01
EPS (Diluted)	-2.11	-1.67	-1.52	-1.88	-1.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-304535.71%	-19187.74%	-6938.77%	-16106.63%	-111163.64%
Profit Margin	-300585.71%	-19360.00%	-7299.20%	-16762.43%	-109990.91%
EBIT	-42.64	-29.74	-25.95	-29.15	-12.23

Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q